0001415889-17-001001.txt : 20170615
0001415889-17-001001.hdr.sgml : 20170615
20170615131440
ACCESSION NUMBER: 0001415889-17-001001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20170615
DATE AS OF CHANGE: 20170615
EFFECTIVENESS DATE: 20170615
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: AzurRx BioPharma, Inc.
CENTRAL INDEX KEY: 0001604191
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-288822
FILM NUMBER: 17912997
BUSINESS ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
BUSINESS PHONE: 646-699-7855
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharma d'Azur, Inc.
DATE OF NAME CHANGE: 20140331
D
1
primary_doc.xml
X0707
D
LIVE
0001604191
AzurRx BioPharma, Inc.
760 Parkside Avenue
Suite 304
Brooklyn
NY
NEW YORK
11226
646-699-7855
DELAWARE
None
BioPharma d'Azur, Inc.
Corporation
true
2014
Johan
M.
Spoor
c/o AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Director
Edward
M.
Borkowski
c/o AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Alastair
M.
Riddell
c/o AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Maged
M.
Shenouda
c/o AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Charles
M.
Casamento
c/o AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Biotechnology
Decline to Disclose
- 06b
false
2017-06-05
false
true
true
false
0
Alexander Capital, LP
40077
None
None
17 State Street
5th Floor
New York
NY
NEW YORK
10004
CO
COLORADO
CT
CONNECTICUT
DE
DELAWARE
FL
FLORIDA
MA
MASSACHUSETTS
NJ
NEW JERSEY
NY
NEW YORK
RI
RHODE ISLAND
SC
SOUTH CAROLINA
TX
TEXAS
5000000
5000000
0
false
0
27
311800
true
0
0
true
Company requires short-term working capital to fund certain operating costs.
AzurRx BioPharma, Inc.
/s/ Johan M. Spoor
Johan M. Spoor
President and CEO
2017-06-15